Jorge E. Cortes, MD
Ponatinib, an oral multikinase inhibitor, generated significant responses in more than 50% of patients with certain chronic myeloid leukemia (CML) subtypes, in a phase II trial intended to pave the way for a regulatory submission. The benefit reached 70% for some patients with CML who also harbored a T315I
Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. PACE: a pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. J Clin Oncol. 2012;30(suppl; abstr 6503).
... to read the full story